Population-Based Multicenter Real-World Outcomes of Encorafenib Plus Panitumumab in BRAF V600E-Mutated Metastatic Colorectal Cancer.

Background

The BRAF V600E mutation in metastatic colorectal cancer (mCRC) is associated with a poor prognosis when treated with conventional chemotherapy regimens. Recent advances in research have shown promise in using combined BRAF inhibitor and an EGFR inhibitor to treat BRAF V600E-mutated mCRC, with international guidelines recommending this combination for patients who have progressed after chemotherapy. However, there is limited real-world evidence evaluating the uptake and outcomes of this regimen. Hence, we sought to evaluate the baseline characteristics, treatment patterns, outcomes, and health care resource utilization (HCRU) of BRAF V600E mutated stage IV mCRC patients receiving encorafenib (BRAFi) plus panitumumab (EGFRi) in Alberta, Canada.

Materials And Methods

We conducted an observational study retrospectively analyzing population-level secondary data supplemented with chart review data from Alberta, Canada.

Results

We identified a total of 43 patients with stage IV mCRC who received encorafenib plus panitumumab in Alberta, Canada between 2018 and 2023. Median overall survival (OS) was 13.0 months, while real-world progression-free survival was 5.6 months for this cohort. Dose reductions for panitumumab occurred in 2 patients, and 12 patients had a dose reduction of encorafenib. Health care utilization for patients receiving this regimen was low, as the mean number of hospital visits and emergency visits within the first year of treatment was 5.2 and 3.4 visits, respectively.

Conclusion

Encorafenib and panitumumab can be effectively combined to treat stage IV mCRC in patients with BRAF V600E mutation. Real-world outcomes indicate that the combination is tolerated with meaningful clinical efficacy.